v3.25.4
Revenue - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2021
May 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]            
Revenue $ 559,000 $ 43,258,000 $ 31,643,000      
Upfront cash payment received 55,622,000 52,096,000 $ 81,572,000      
Collaboration Agreement with AstraZeneca            
Disaggregation of Revenue [Line Items]            
Revenue 600,000 18,000,000        
Upfront cash payment received         $ 40,000,000 $ 20,000,000
Milestone payments received 0 10,000,000        
Collaboration Agreement with Hansoh            
Disaggregation of Revenue [Line Items]            
Revenue 0 24,600,000        
Upfront cash payment received       $ 16,000,000    
Upfront cash payments received, net of tax       $ 14,400,000    
Milestone payments received 0 2,000,000        
Royalty Income            
Disaggregation of Revenue [Line Items]            
Revenue 0 144,000        
Research Collaboration Income            
Disaggregation of Revenue [Line Items]            
Revenue $ 559,000 $ 43,114,000